Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 134Breast Neoplasms 94Colorectal Neoplasms 65Carcinoma, Hepatocellular 57Squamous Cell Carcinoma of Head and Neck 48Stomach Neoplasms 46Lung Neoplasms 45Triple Negative Breast Neoplasms 43Prostatic Neoplasms 43Leukemia, Myeloid, Acute 43Small Cell Lung Carcinoma 41Uterine Cervical Neoplasms 40Rectal Neoplasms 37Neoplasms 31Pancreatic Neoplasms 30Recurrence 29Neoplasm Metastasis 29Esophageal Squamous Cell Carcinoma 25Esophageal Neoplasms 24Ovarian Neoplasms 23Nasopharyngeal Carcinoma 21Brain Neoplasms 21Melanoma 20Lymphoma, Large B-Cell, Diffuse 20Colonic Neoplasms 20Carcinoma, Renal Cell 20Head and Neck Neoplasms 19Endometrial Neoplasms 19Multiple Myeloma 18Biliary Tract Neoplasms 18

Interventions

irinotecan sucrosofate 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Efficacy and Safety × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡